Dulaglutide, a convenient weekly injectable with strong glycemic efficacy and potential for weight loss, emerges as a promising new GLP‐1 RA for the treatment of obesity even in patients with multiple comorbidities. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.